𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized, controlled pilot trial of interferonα (IFN) with or without thymosinα1 (TA1) in naive chronic hepatitis C (CHC)

✍ Scribed by A. Gramenzi; L. Di Giammarino; C. Cursaro; F. Felline; S. Talarico; A. D'Errico; R. Carella; M. Biselli; P. Andreone; M. Bernardi

Book ID
119526351
Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
112 KB
Volume
32
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of thymosin α1 in patients with
Efficacy of thymosin α1 in patients with chronic hepatitis B: A randomized, controlled trial
✍ Rong-Nan Chien; Yun-Fan Liaw; Tse-Ching Chen; Chau-Ting Yeh; I.-Shyan Sheen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 1 views

Thymosin ␣ 1 (T␣) is an immune modifier that has been shown in a pilot study to be effective for chronic hepatitis B; this requires confirmation. Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups: 1) group A received a 26-week course of T

Combination therapy with thymosin α1 and
Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr